Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.

Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez ML, Huledal G, Kolly C, Lüönd RM, Machauer R, Veenstra SJ, Hurth K, Rueeger H, Tintelnot-Blomley M, Staufenbiel M, Shimshek DR, Perrot L, Frieauff W, Dubost V, Schiller H, Vogg B, Beltz K, Avrameas A, Kretz S, Pezous N, Rondeau JM, Beckmann N, Hartmann A, Vormfelde S, David OJ, Galli B, Ramos R, Graf A, Lopez Lopez C.

EMBO Mol Med. 2018 Sep 17. pii: e9316. doi: 10.15252/emmm.201809316. [Epub ahead of print]

2.

Determination of Seminal Concentration of Fingolimod and Fingolimod-Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod.

David OJ, Berwick A, Pezous N, Lang M, Tiel-Wilck K, Ziemssen T, Li P, Hara H, Schmouder R.

Clin Pharmacol Drug Dev. 2018 Feb;7(2):217-221. doi: 10.1002/cpdd.424. Epub 2017 Dec 19.

3.

The selective metabotropic glutamate receptor 5 antagonist mavoglurant (AFQ056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease.

Rouzade-Dominguez ML, Pezous N, David OJ, Tutuian R, Bruley des Varannes S, Tack J, Malfertheiner P, Allescher HD, Ufer M, Rühl A.

Neurogastroenterol Motil. 2017 Aug;29(8). doi: 10.1111/nmo.13058. Epub 2017 Mar 23.

PMID:
28337838
4.

Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial.

Barch DM, Marder SR, Harms MP, Jarskog LF, Buchanan RW, Cronenwett W, Chen LS, Weiss M, Maguire RP, Pezous N, Feuerbach D, Lopez-Lopez C, Johns DR, Behrje RB, Gomez-Mancilla B.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Nov 3;71:66-75. doi: 10.1016/j.pnpbp.2016.06.013. Epub 2016 Jun 28.

PMID:
27371157
5.

Cardiac Effects of Siponimod (BAF312) Re-initiation After Variable Periods of Drug Discontinuation in Healthy Subjects.

Legangneux E, Shakeri-Nejad K, Aslanis V, Sagkriotis A, Pezous N, Brendani B, Behrje R, Gutierrez M.

Clin Ther. 2016 Mar;38(3):631-45.e1. doi: 10.1016/j.clinthera.2016.01.021. Epub 2016 Feb 23.

PMID:
26916566
6.

Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.

Shakeri-Nejad K, Aslanis V, Veldandi UK, Mooney L, Pezous N, Brendani B, Juan A, Allison M, Perry R, Legangneux E.

Clin Ther. 2015 Nov 1;37(11):2489-2505.e2. doi: 10.1016/j.clinthera.2015.09.006. Epub 2015 Oct 27.

PMID:
26519230
7.

A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease.

Reilmann R, Rouzade-Dominguez ML, Saft C, Süssmuth SD, Priller J, Rosser A, Rickards H, Schöls L, Pezous N, Gasparini F, Johns D, Landwehrmeyer GB, Gomez-Mancilla B.

Mov Disord. 2015 Mar;30(3):427-31. doi: 10.1002/mds.26174. Epub 2015 Feb 17.

PMID:
25689146
8.

AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.

Feuerbach D, Pezous N, Weiss M, Shakeri-Nejad K, Lingenhoehl K, Hoyer D, Hurth K, Bilbe G, Pryce CR, McAllister K, Chaperon F, Kucher K, Johns D, Blaettler T, Lopez Lopez C.

Br J Pharmacol. 2015 Mar;172(5):1292-304. doi: 10.1111/bph.13001. Epub 2015 Jan 12.

9.

Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks.

Gomez-Mancilla B, Brand R, Jürgens TP, Göbel H, Sommer C, Straube A, Evers S, Sommer M, Campos V, Kalkman HO, Hariry S, Pezous N, Johns D, Diener HC; BGG492 Study Group.

Cephalalgia. 2014 Feb;34(2):103-13. doi: 10.1177/0333102413499648. Epub 2013 Aug 20.

PMID:
23963355
10.

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP; Secukinumab in Crohn's Disease Study Group.

Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668. Epub 2012 May 17.

11.

Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study.

Schaefer F, Litwin M, Zachwieja J, Zurowska A, Turi S, Grosso A, Pezous N, Kadwa M.

J Hypertens. 2011 Dec;29(12):2484-90. doi: 10.1097/HJH.0b013e32834c625c.

PMID:
22025233
12.

Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.

Vandel P, Sechter D, Weiller E, Pezous N, Cabanac F, Tournoux A, Panconi E.

Hum Psychopharmacol. 2004 Dec;19(8):585-6. No abstract available.

PMID:
15570574
13.

A comparative study of milnacipran and paroxetine in outpatients with major depression.

Sechter D, Vandel P, Weiller E, Pezous N, Cabanac F, Tournoux A; study co-coordinators.

J Affect Disord. 2004 Dec;83(2-3):233-6.

PMID:
15555719
14.
15.

Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode.

Tignol J, Pujol-Domenech J, Chartres JP, Léger JM, Plétan Y, Tonelli I, Tournoux A, Pezous N.

Acta Psychiatr Scand. 1998 Feb;97(2):157-65.

PMID:
9517912

Supplemental Content

Loading ...
Support Center